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Survival analysis is routinely used to assess 
differences between groups in relapse prevention 
and treatment discontinuation studies involving 
people with long- term psychiatric conditions. The 
actual outcome in survival analysis is ‘time to 
event’, yet, in the mental health field, there has 
been little consideration of whether a temporary 
delay to relapse is clinically relevant in a 
condition that can last for decades. Moreover, in 
psychiatric drug trials, a pattern of elevated early 
relapses following randomisation to placebo or 
no treatment is common. This may be the result 
of the withdrawal of previous treatment leading 
to physiological withdrawal effects, which may 
be mistaken for relapse, or genuine relapse 
precipitated by the process of withdrawal. Such 
withdrawal effects typically produce converging 
survival curves eventually. They inevitably lead 
to differences in time to relapse, even when there 
is little or no difference in the cumulative risk of 
relapse at final follow- up. Therefore, statistical 
tests based on survival analyses can be misleading 
because they obscure these withdrawal effects. We 
illustrate these difficulties in a trial of antipsychotic 
reduction versus maintenance, and a trial of 
prophylactic esketamine in people with treatment- 
resistant depression. Both illustrate withdrawal- 
related effects that underline the importance of 
long- term follow- up and question the use of tests 
based on time to event. Further discussion of the 
most relevant outcome and appropriate approach 
to analysis, and research on patient and carer 
preferences is important to inform the design of 
future trials and interpretation of existing ones.
Introduction
Survival analysis was initially developed to 
analyse risk of death over time, but is now used 
for the analysis of many categorical outcomes 
in health research, including relapse of mental 
health conditions. The outcome survival analysis 
assesses is the time to the outcome or ‘event’ in 
question. Common methods include Cox regres-
sion analysis, which produces a Hazard Ratio 
(HR) and is dependent on the assumption that 
the ratio between the hazard rates in the two 
groups is constant over time (proportional hazards 
assumption). The rank sum test does not make this 
assumption and tests the statistical significance of 
the difference in the overall survival time between 
the groups but does not yield an effect estimate. 
The Kaplan Meier method graphically describes 
survival over time.
Tests of differences between groups based on 
survival analysis are statistically efficient when 
the duration of participants’ follow- up varies, and 
therefore commonly preferred to the alternative 
method of comparing the proportion of events at a 
particular time.1 2 Limitations to do with censoring 
and low precision of the last stages of survival 
curves are well- recognised.3 In the following 
paragraphs, we consider problems of analysing 
studies of drug treatment for relapse prevention in 
psychiatric conditions. These follow from the fact 
that survival analysis depends on the time it takes 
for an event to occur, combined with the potential 
for withdrawal of previous drug treatment to exert 
a differential influence on the risk of relapse in 
intervention trials that employ a discontinuation 
design.
Time to event is not necessarily the key outcome
Survival analysis is useful when the timing of the 
outcome is of importance and depends on people 
wanting to avoid early adverse events more than 
late ones. Tests based on survival analysis may 
show highly significant results if relapse is delayed 
by a few weeks, for example. However, the clin-
ical relevance of a temporary delay in relapse in 
a long- term psychiatric condition that may last 
for decades has not been established, and statis-
tically significant results are a questionable basis 
for implementing an intervention that may be of 
limited importance to patients. There has been no 
published research or discussion about whether 
patients, carers or clinicians consider a delay in 
relapse to be important, the minimum length of 
delay that would qualify, and how these views 
are influenced by the possible causes of relapse. 
Despite the widespread use of survival analysis 
there has been little consideration of its implica-
tions or how it compares with other approaches. 
In an analysis of relapse definitions in 81 trials of 
antipsychotics, for example, none of them consid-
ered whether time to relapse or overall risk was 
more relevant.4
Non-proportional hazards
If follow- up is short, differences between groups 
may be misleading, because short- term differ-
ences may not persist with longer term follow- up. 
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In other words, it cannot be assumed that the HR or risk ratio 
between the groups remains constant over a longer duration. The 
difficulties caused by non- proportional hazards or risks when 
survival curves converge or cross are well- recognised by statisti-
cians, yet frequently ignored when trials are reported.5 In theory, 
a single HR is misleading in this situation, and Cox regression, 
which depends on the assumption of proportional hazards, should 
not be conducted. In practice, non- proportional hazards are 
common, but the proportional hazards assumption is frequently 
not tested and single HRs are often quoted.5 Although the log rank 
test is technically correct in this situation, since it simply tests for 
a difference in the survival curves without assuming proportional 
hazards, it does not account for the pattern of the curves and 
its use forecloses discussion about the causes of varying hazards. 
Therefore, the use of the log rank test may also lead to misleading 
results, or at least results that are difficult to interpret clinically.6
Various statistical solutions have been proposed to manage 
situations in which non- proportional hazards are found.6 7 
However, these are still based on ‘time to event’ analysis, and 
hence assume that delaying the event is the key desirable outcome.
Withdrawal effects in psychiatric trials
Trials of long- term treatment in psychiatry, including trials 
referred to as relapse prevention trials, employ a discontinuation 
design in which the withdrawal of previous treatment is compared 
with its continuation. Many trials of psychiatric drugs, including 
antipsychotics, antidepressants and lithium8–11 reveal that people 
randomised to switch to placebo or no treatment show a high rate 
of early relapse that declines over subsequent months or years 
(eg, see figures 1 and 2). This high rate of early relapse is absent 
or less marked in those randomised to continue treatment, and 
hence there are substantial differences in relapse rates to begin 
Figure 1 Time to relapse (days) among people with first- episode psychosis randomised to maintenance antipsychotic treatment (MT) or supported 
reduction (DR). Reproduced with permission from Wunderink et al.8 Copyright (2013) American Medical Association. All rights reserved.5 DR, 
discontinuation; MT, maintenance treatment.
Figure 2 Time to relapse among people with treatment- resistant depression randomised to esketamine plus antidepressant or placebo plus 
antidepressant. Reprinted from Singh et al.34 Copyright (2020) with permission from Elsevier.21
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with, which diminish over time, as demonstrated in meta- analyses 
of antipsychotic and antidepressant relapse prevention trials, for 
example.12–14 The reasons for the high rate of early relapse are 
debated and several possibilities exist.15 It has been argued that 
it reflects a naturally high risk of relapse in some disorders, such 
as schizophrenia,16 but the untreated risk in most psychiatric 
disorders, including schizophrenia, is not known. Where historical 
evidence exists, as in bipolar disorder, it suggests the underlying 
risk is lower than following discontinuation of drug treatment.17 18 
In a chronic condition, early relapses might also represent the 
re- emergence of underlying symptoms previously suppressed by 
the drugs, but this is only likely to explain a small number of early 
relapses, since most people do not have severe, chronic symptoms 
and long- term medication is generally prescribed for prophylaxis. 
Another possibility is that the withdrawal of previous treatment 
increases the risk of adverse outcomes above their ‘baseline’ level, 
due to the occurrence of withdrawal effects or of a relapse that is 
caused by the process of withdrawal.
It is well- established that psychiatric drugs of all kinds 
produce physiological withdrawal effects when they are stopped, 
especially if people have been using them for long periods.19 These 
are manifested in physical and psychological symptoms, and may 
be mistaken for relapse, since symptoms overlap and there are no 
definitive ways of distinguishing the two situations.20 Although 
withdrawal symptoms are traditionally thought to be short- lived, 
accumulating evidence suggests they can sometimes be protracted 
over many weeks or months.21–23 In addition to this, withdrawal 
may itself precipitate relapse of some conditions, including 
schizophrenia or psychosis and bipolar disorder, elevating the risk 
of relapse for several months.19 24 25 Studies of lithium treatment 
in people diagnosed with bipolar disorder, for example, show that 
the risk of developing an episode following the discontinuation of 
lithium is higher than it was prior to lithium being started.10 26 27 
The fact that some evidence suggests relapse is less likely with 
gradual compared with abrupt discontinuation also supports the 
possibility that it may be precipitated by medication withdrawal.28
Survival analysis in the presence of withdrawal effects
Several commentators have highlighted how withdrawal effects 
confound the interpretation of relapse prevention studies.15 19 24 25 
These studies may not, in fact, provide reliable data about the 
benefits of starting long- term medication, only about the adverse 
effects of stopping it. Nevertheless, trials of treatment discontin-
uation are valuable since many people are established on long- 
term treatment that may not be beneficial or that they want to 
stop. Whatever the purpose of a treatment withdrawal trial, the 
pattern of adverse outcomes following randomisation is impor-
tant to understand. Survival curves can be helpful in illustrating 
such patterns if follow- up is long enough for withdrawal effects 
to evolve and dissipate. However, a single, global test of the 
difference between those who continue on treatment and those 
who withdraw over the whole period based on the time to relapse 
obscures these effects. This is important because the occurrence 
of withdrawal effects may affect how people view the desirability 
of remaining on, or coming off treatment. Moreover, such tests 
are often presented as if they are equivalent to tests of cumula-
tive differences in risk at the end of follow- up. In a situation of 
constant hazards this is the case, but where hazards rates diverge 
or cross, results of tests based on survival analysis may conflict 
with tests of the eventual cumulative risk ratio. As figures 1 and 
2 illustrate, if survival curves show an early divergence and then 
meet, tests based on the overall difference of survival curves 
will indicate a positive effect for the treatment that produces the 
fewest early relapses, but tests based on the cumulative risks at 
later follow- up may show no difference. Two examples illustrate 
these arguments.
Example 1: antipsychotics and relapse prevention in first-episode 
psychosis
A trial conducted in the Netherlands comparing antipsychotic 
discontinuation with maintenance treatment in people with a first 
episode of psychosis followed people up initially at 18 months and 
then again after 7 years.
At the 18- month follow- up, the survival analysis revealed a 
constant HR, which was estimated by Cox regression analysis and 
indicated that the risk of relapse was increased by 2.3 times in the 
group randomised to discontinuation.29
Data from the 7- year follow- up, however, showed that survival 
curves converged at around 3 years and then crossed; therefore, 
the proportional hazard assumption of Cox regression would not 
be fulfilled (figure 2).8 A log rank test would likely indicate an 
advantage for the maintenance group, however, because of the 
more frequent earlier occurrence of relapses in the discontinuation 
group.
As discussed, there is no evidence about whether people value 
a delay in relapse in this situation, and if they do, what dura-
tion of delay would balance out the considerable adverse effects 
associated with antipsychotics; furthermore there is evidence 
from the long- term follow- up of this particular trial that anti-
psychotics may impair social functioning.8 Although antipsy-
chotics were reduced more gradually in this than in other studies, 
the fact that the excess risk of relapse occurred early on in the 
group randomised to antipsychotic reduction suggests it may have 
been associated with the process of discontinuation. The study 
demonstrates the importance of long- term follow- up, and of not 
assuming that short- term outcomes are equivalent to long- term 
outcomes. The HR generated at the 18 month follow- up is not 
equivalent to the ratio of the cumulative proportions of people 
relapsing after 7 years, even though hazards were initially propor-
tional. Use of the log rank test would obscure this withdrawal 
effect. Therefore, the cumulative proportion of people relapsing at 
different follow- up points, including the final follow- up, would be 
a better test of the overall outcome in this situation. This is what 
the authors presented in the follow- up report.5
Example 2: esketamine for relapse prevention in treatment-
resistant depression
A further example is provided by the results of a relapse preven-
tion trial of esketamine for people with treatment resistant depres-
sion.30 Although esketamine is a relatively new preparation, 
withdrawal symptoms following recreational use of ketamine (a 
similar drug) are recognised, and include low mood and anxiety, 
which may be mistaken for relapse.31 Psychological factors may 
also precipitate relapse following withdrawal, since significant 
unblinding is likely to occur after switching to placebo (due to 
loss of the psychoactive effects of esketamine), leading to anxiety 
about treatment withdrawal.
The original analysis of this trial was performed using the 
Kaplan Meier method and the log rank test showed a significant 
difference between esketamine and placebo (p=0.003). Survival 
curves indicated varying HRs but did not cross. The maximum 
divergence of risk between the groups occurred within the first 
8 weeks following randomisation, suggesting a likely withdrawal 
effect. Although the authors of the esketamine trial asserted there 
was no evidence of a withdrawal syndrome, no details were 
provided, and it was not explained how relapse was distinguished 
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from possible withdrawal.30 Subsequent data from this study and 
from others suggest that withdrawal symptoms occur commonly, 
are similar to those reported with ketamine,32 and may be inter-
preted as a relapse of depression.
A letter published in response to this trial pointed out that 
results were strongly influenced by an ‘outlier’ site that reported 
a particularly large difference between the groups. The author 
of the letter analysed the data excluding this site by comparing 
the proportions of participants relapsing in both groups over the 
whole trial duration using the Fisher’s exact test.33 This found 
no statistically significant difference between the groups (p=0.13). 
The authors of the original trial objected that this was not the best 
way to analyse the data and applied survival analysis, as they had 
done in the original trial report.34 This revealed survival curves 
that crossed at around 9 months of follow- up (figure 2). The log 
rank test was used to compare the groups and indicated a statis-
tically significant difference (p=0.048), and Cox regression was 
apparently used to estimate a HR.
As the proportional hazards assumption is violated because 
the survival curves converge, it is incorrect to use Cox regression 
to calculate an overall HR, but the log rank test could also be 
misleading, because it obscures the convergence of the survival 
curves after what appears to be an early withdrawal effect. 
Treatment resistant depression is a long- term condition, and no 
research has yet clarified whether delaying symptom recurrence 
for a few months would outweigh adverse effects or represent 
value for money. It is also important to recognise the likelihood 
of a withdrawal effect, rather than to assume that the difference 
between the groups is the result of the treatment per se. Evidence 
of a withdrawal effect has a bearing on the cost- benefit analysis 
of starting treatment, and is particularly important in view of the 
fact that acute trials of esketamine have not demonstrated a clin-
ically relevant effect.35
Patient and public involvement
There was no direct patient and public involvement in the prepa-
ration of this article, due to the lack of funding. However, there 
is a high degreee of concern among patients and the public about 
withdrawal effects from psychiatric drugs and how their impact 
has been misunderstood and underestimated.36 The article was 
partly inspired by the first author’s discussions with patients who 
are concerend about the interpretation of randomised drug trials.
Conclusion
Both examples illustrate how survival analysis may be misleading 
because it obscures a possible withdrawal effect, and delaying 
time to relapse has not been established as a worthwile outcome. 
Both studies also underline the importance of conducting long- 
term follow- up, since the outcomes of different interventions 
and treatment approaches can vary over time. Further research is 
needed on how patients and carers value a delay in relapse, and 
further debate is required about whether time to relapse should 
be preferred over the overall risk of relapse, especially in view 
of withdrawal- related adverse effects. Until then, we suggest that 
survival analysis should not be routinely employed in trials of 
interventions aimed at relapse prevention in long- term psychi-
atric conditions. Statistical methods for comparing proportions, 
such as the χ2 test or logistic regression, should be used instead, 
complemented by Kaplan Meir survival curves to illustrate the 
timing of outcomes.
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